---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-001308"
form_type: "8-K"
ticker: "SHPH"
cik: "0001757499"
company_name: "Shuttle Pharmaceuticals Holdings, Inc."
filed_at: "2023-01-12T23:59:59+00:00"
generated_at: "2026-06-20T16:05:29.885731+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Shuttle Pharmaceuticals issues $4.3M convertible note and warrant, receives $4M gross proceeds

## Summary
- Issued $4.3M senior secured convertible note to Alto Opportunity Master Fund; gross proceeds $4.0M.
- Warrant to purchase 1,018,079 shares at $2.35/share, exercisable for 4 years, potential additional $2.4M.
- Note amortizes over 26 months, 5% interest; conversion price tied to discounted VWAP formulas.
- Full security interest on all assets and IP; springing deposit account control if default.
- Boustead Securities placement agent received $320,000 cash and a warrant for 71,266 shares.

## SEC filing metadata
- accession: 0001493152-23-001308
- form_type: 8-K
- ticker: SHPH
- cik: 0001757499
- company_name: Shuttle Pharmaceuticals Holdings, Inc.
- filed_at: 2023-01-12T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1757499/000149315223001308/0001493152-23-001308-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1757499/000149315223001308/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-001308
- JSON: https://secwatch.observer/filing/0001493152-23-001308.json
- Plain text: https://secwatch.observer/filing/0001493152-23-001308.txt

## Key facts
- Material Agreements
  Shuttle Pharmaceuticals Holdings, Inc. entered into SPA with Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B valued at $4.3 million convertible note (effective 2023-01-11).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B
  - Value: $4.3 million convertible note
  - Effective: 2023-01-11
  source text: On January 11, 2023, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “SPA”) with Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B, a Cayman entity (the “Investor”), pursuant to which the Company sold to the Investor a $4.3 million convertible note (the “Convertible Note”) and warrant (the “Warrant”) to purchase 1,018,079 shares of common stock, par value $0.00001 per share (“Common Stock”), in exchange for gross proceeds of $4.0 million (the “Investment Amount”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1757499/000149315223001308/0001493152-23-001308-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.